The authors found one-time screening of the general population at the age of 55 years, with the addition of SGLT2-inhibition treatment on top of conventional RAAS-inhibition therapy for those identified with CKD, to be cost-effective at an ICER of $86 300 per QALY. This evidence concerns the gene SLC5A2 and chronic kidney disease.